Shares Magazine
232.50p-10.00 (-4.12%)15 Apr 2021, 16:42
Jump to:
Oncimmune Holdings PLC Fundamentals
| Company Name | Oncimmune Holdings PLC | Last Updated | 2021-04-15 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 69.098 m | Market Cap | £160.65 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.13 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 1.0955 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | -3.9498 | Cash Equity Ratio | -1.3526 |
| Quick Ratio | 1.7911 | Current Ratio | 1.89 |
| Price To Book Value | 0 | ROCE | 0 |
Oncimmune Holdings PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Oncimmune Holdings PLC Company Financials
| Assets | 2020 | 2019 | 2018 |
|---|---|---|---|
| Tangible Assets | £1.37 m | £422,000.00 | £201,000.00 |
| Intangible Assets | £2.72 m | £3.01 m | £671,000.00 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £4.09 m | £3.43 m | £872,000.00 |
| Stocks | £174,000.00 | £292,000.00 | £295,000.00 |
| Debtors | £1.79 m | £325,000.00 | £291,000.00 |
| Cash & Equivalents | £4.24 m | £5.36 m | £12.95 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £10.31 m | £9.43 m | £14.41 m |
| Liabilities | 2020 | 2019 | 2018 |
|---|---|---|---|
| Creditors within 1 year | £3.47 m | £1.06 m | £849,000.00 |
| Creditors after 1 year | £7.04 m | £506,000.00 | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £10.51 m | £1.57 m | £849,000.00 |
| Net assets | -£194,000.00 | £7.87 m | £13.56 m |
| Equity | 2020 | 2019 | 2018 |
|---|---|---|---|
| Called up share capital | £635,000.00 | £633,000.00 | £616,000.00 |
| Share Premium | £31.46 m | £31.38 m | £30.95 m |
| Profit / Loss | -£9.78 m | -£8.55 m | -£6.34 m |
| Other Equity | -£194,000.00 | £7.87 m | £13.56 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | -£194,000.00 | £7.87 m | £13.56 m |
| Ratios | 2020 | 2019 | 2018 |
|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 |
| Debt-to-Equity | 0 | 0 | 0 |
| Assets / Equity | -3.9498 | -3.9498 | -3.9498 |
| Cash / Equity | -1.3526 | -1.3526 | -1.3526 |
| EPS | -£0.14 | -£0.13 | -£0.11 |
| Cash Flow | 2020 | 2019 | 2018 |
|---|---|---|---|
| Cash from operating activities | -£8.90 m | -£7.36 m | -£6.10 m |
| Cashflow before financing | -£1.44 m | -£7.43 m | £8.18 m |
| Increase in Cash | -£1.12 m | -£7.59 m | £7.88 m |
| Income | 2020 | 2019 | 2018 |
|---|---|---|---|
| Turnover | £509,000.00 | £171,000.00 | £240,000.00 |
| Cost of sales | £537,000.00 | £1.03 m | £917,000.00 |
| Gross Profit | -£28,000.00 | -£859,000.00 | -£677,000.00 |
| Operating Profit | -£9.27 m | -£8.59 m | -£6.37 m |
| Pre-Tax profit | -£9.78 m | -£8.55 m | -£6.34 m |
Oncimmune Holdings PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. The company's operating segment includes EarlyCDT and ImmunoINSIGHTS. It generates maximum revenue from the EarlyCDT segment. |
| Latest Interim Date | 15 Feb 2021 |
| Latest Fiscal Year End Date | 30 Oct 2020 |
Oncimmune Holdings PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2016-11-07 | Mr. Andrew Vaughan Unitt | Non-Executive Director |
| 2020-05-04 | Mr. Richard Simon Sharp | Non-Executive Director |
| 2020-09-11 | Mr. Meinhard Folkert Schmidt | Non-Executive Director,Chairman |
| 2020-06-04 | Mr. Geoffrey Neil Hamilton-Fairley | Non-Executive Director,Vice Chairman |
| 2016-06-06 | Mr. Robert Hoyles Page | Executive Director,Chief Financial Officer |
| 2020-06-05 | Mr. Timothy Brian Bunting | Non-Executive Director,Deputy Chairman |
| 2019-11-05 | Mr. Andrew Millet | Executive Director,Chief Financial Officer and Company Secretary |
| 2020-06-04 | Mr. Carsten Schroeder | Non-Executive Director |
| 2020-12-18 | Dr. Adam Mark Hill MB PhD | Executive Director,Chief Executive Officer |
| 2021-01-19 | Dr. To Cheung | Non-Executive Director |
| 2019-11-05 | Mr. Matthew Hall | Executive Director,Chief Financial Officer |
Oncimmune Holdings PLC Contact Details
| Company Name | Oncimmune Holdings PLC |
|---|---|
| Address | Hucknall Road, Clinical Sciences Building, City Hospital, Nottingham, NG5 1PB |
| Telephone | |
| Website | https://www.oncimmune.com |
Oncimmune Holdings PLC Advisors
| Nominated Adviser | Zeus Capital Ltd |
|---|---|
| Phone | +44 2038295000 |
| Auditor | Grant Thornton (UK) LLP |
|---|---|
| Phone | +44 1908660666 |
| Fax | +44 1908690180 |
| Stockbroker | Zeus Capital Ltd |
|---|---|
| Phone | +44 2038295000 |
| Registrar | Capita Asset Services |
|---|---|
| Phone | +44 8716640300 |
| Fax | +44 2086392342 |
| Financial PR Adviser | Consilium Strategic Communications |
|---|---|
| Phone | +44 2037095700 |
| Solicitor | Peachey & Co LLP |
|---|---|
| Phone | (020) 7316 5200 |
| Fax | (020) 7316 5222 |
Sign up to our
daily email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Countryside Properties PLC | 541.00 | 5.05 |
| Future PLC | 2,348.00 | 5.01 |
| Smurfit Kappa Group PLC | 3,570.00 | 4.72 |
| Glaxosmithkline PLC | 1,348.40 | 4.56 |
| Mondi PLC | 1,942.50 | 3.74 |
| Trainline PLC | 489.80 | 3.51 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Legal & General Group PLC | 276.10 | -5.02 |
| Osb Group PLC | 471.80 | -4.53 |
| Jupiter Fund Management PLC | 276.80 | -3.96 |
| Syncona Limited | 233.00 | -3.52 |
| Ssp Group PLC | 304.00 | -3.49 |
| Carnival PLC | 1,670.20 | -3.43 |
